Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.


Search Results to Timothy L Vollmer

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following items that are connected to Vollmer, Timothy

Item TypeName
Academic Article Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].
Academic Article An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
Academic Article Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.
Academic Article Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry.
Academic Article Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis.
Academic Article Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Academic Article Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Academic Article Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation.
Academic Article Lifestyle physical activity and walking impairment over time in relapsing-remitting multiple sclerosis: results from a panel study.
Academic Article Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis.
Academic Article Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.
Academic Article Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Academic Article Oral simvastatin treatment in relapsing-remitting multiple sclerosis.
Academic Article The natural history of relapses in multiple sclerosis.
Academic Article Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric Model.
Academic Article Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Academic Article Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Academic Article Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.
Academic Article Continued validation of the Symptom Inventory in multiple sclerosis.
Academic Article B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Academic Article Physical activity correlates with neurological impairment and disability in multiple sclerosis.
Academic Article A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Academic Article Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Academic Article Glatiramer acetate-specific antibody titres in patients with relapsing?/?remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.
Academic Article Natalizumab-associated complication? First case of peripheral T cell lymphoma.
Concept Multiple Sclerosis, Relapsing-Remitting
Academic Article Multiple sclerosis: Oral laquinimod for MS--bringing the brain into focus.
Academic Article Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Academic Article Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study.
Academic Article Incorporating real-world clinical practice in multiple sclerosis economic evaluations.
Academic Article Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Academic Article Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Academic Article Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.
Academic Article Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
Academic Article Analysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory.
Academic Article Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.
Academic Article Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
Academic Article Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
Academic Article Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.
Academic Article CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.

Search Criteria
  • Multiple Sclerosis Relapsing Remitting

Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)